Genomic Vision announced Tuesday that it has entered into a technology agreement with The Institute of Cancer Research, a London-based cancer research institute.

Under the terms of the partnership, Genomic will provide the academic institution with its state-of-the-art fluorescence scanner for molecular combing, FiberVisionS, as well as its advanced AI algorithm FiberSmart.

The agreement with ICR, known for its expertise in oncology drug discovery, includes a one-off upfront payment with the possibility of additional recurring revenues from the sale of consumables, the biotech company says.

Following this order, Genomic Vision shares were up 1.5% on Tuesday on the Paris Bourse.

Copyright (c) 2023 CercleFinance.com. All rights reserved.